Innovent expands portfolio, lifts H1 profit
Innovent Biologics reported H1 2025 revenue of RMB 5.95 billion, up 50.6% YoY, and net profit of RMB 1.21 billion. The company expanded its portfolio to 16 drugs, including three new oncology launches, advanced global pipeline trials, and reaffirmed its target of RMB 20 billion product revenue by 2027.